AG真人官方

Septerna, Inc. reporting person Elizabeth Bhatt, President and COO, was granted a stock option to acquire 95,000 shares of common stock with an $11.70 exercise price. The transaction is reported with a transaction date of 08/07/2025 and the option appears as a direct holding following the grant.

The option vests in equal monthly installments equal to 1/48th of the shares beginning August 1, 2025, subject to continued service, and the instrument shows an expiration date of 08/06/2035. The filing documents the grant terms but does not disclose the company鈥檚 outstanding share count or any cash paid for the award.

Septerna, Inc. reported a compensatory stock option grant to its Chief Medical Officer, Kim Jae B. The award is a stock option to purchase 55,000 shares of common stock at an exercise price of $11.70 per share. The option grant date is shown as 08/07/2025 and the option expires on 08/06/2035. The option vests in a two-step schedule: 2/48ths of the shares become exercisable on October 1, 2025, with the remaining shares vesting in 46 substantially equal monthly installments thereafter, subject to continuous service. The shares are reported as directly owned following the transaction. This filing documents the terms and vesting timetable of the derivative award to an executive officer.

Septerna, Inc. Form 4 reports that Chief Financial Officer Gil M. Labrucherie acquired a stock option on 08/07/2025 to purchase 37,500 shares of common stock at an exercise price of $11.70 per share. The option is recorded as an acquisition and held directly by the reporting person.

The grant includes a service-based vesting schedule: 6/48th of the option shares vest on February 1, 2026, with the remaining shares vesting in 42 substantially equal monthly installments thereafter, subject to continuous service. The option shows an expiration/related date of 08/06/2035 and 37,500 shares are reported as beneficially owned following the transaction.

Septerna, Inc. (SEPN) reported an equity award to Jeffrey Finer, who serves as Chief Executive Officer and a director. The filing shows a grant of a stock option to purchase 210,000 shares of common stock with an exercise price of $11.70 per share and an expiration date of 08/06/2035. The option vests in equal monthly installments equal to 1/48th of the shares, beginning with the monthly anniversary of August 1, 2025, subject to continuous service.

The reported position after the transaction is direct beneficial ownership of the 210,000 options. This disclosure documents a standard long鈥憈erm incentive award for the CEO with a multi鈥憏ear vesting schedule and a defined exercise price and expiration.

Septerna, Inc. insider Daniel D. Long, the company's SVP of Drug Discovery, received a grant of stock options allowing him to purchase 30,000 shares of Septerna common stock at an exercise price of $11.70 per share.

The option award was recorded with a transaction date of 08/07/2025, carries an expiration date of 08/06/2035, and vests in monthly installments equal to 1/48th of the total award beginning August 1, 2025, subject to continued service. The filing shows the reporting person holds 30,000 options following the transaction and lists the ownership form as direct.

Septerna, Inc. reporting person Uwe Klein, SVP, Biological Sciences, reported acquisition on Form 4 of 30,000 stock options on 08/07/2025. The options carry an exercise price of $11.70 and relate to 30,000 shares of common stock; they are shown as directly owned. The options are listed as exercisable beginning 08/06/2025 and subject to a vesting schedule where 1/48th of the shares vest in substantially equal monthly installments starting August 1, 2025, contingent on the reporting person's continuous service. The form was signed by attorney-in-fact Ran Xiao on 08/11/2025.

Septerna, Inc. reported a net loss of $46.3 million for the six months ended June 30, 2025, compared with a $30.6 million loss in the prior-year period. Revenue remained minimal at $0.3 million for the six months, generated from Vertex research services. Research and development expenses rose to $41.5 million and general and administrative expenses to $13.8 million, driving total operating expenses of $55.2 million. Cash used in operating activities was $43.6 million for the six months. The company had an accumulated deficit of $164.7 million as of June 30, 2025.

The company reported $189.3 million in cash and cash equivalents and $190.0 million of additional marketable securities (current and non-current) for total cash, cash equivalents and marketable securities of approximately $379.2 million, which management states is expected to fund operations for at least 12 months. Material agreements disclosed include a Collaboration and License Agreement with Novo Nordisk for multiple R&D programs with a $195.0 million upfront payment received in July 2025 and potential milestone and royalty payments, and a Vertex milestone payment realized in August 2025 of $12.5 million.

Septerna, Inc. announced that it released its financial results and business highlights for the quarter ended June 30, 2025 and furnished the related press release as Exhibit 99.1 to this Current Report. The filing states the press release is being furnished (and not "filed") for purposes of the Exchange Act, and the 8-K itself does not include detailed financial statements or metrics. Readers should consult Exhibit 99.1 for the substantive results and disclosures.